Profusa, Inc. (PFSA) · Oct 9, 2026 · Auditor change
Auditor change — material weaknesses had not been remediated as of June 30, 2026
Profusa changed auditors, but its new 8-K confirms unresolved financial-control weaknesses and an earlier going-concern warning remain central.
Profusa is a commercial-stage digital-health company developing injectable biosensors and AI-driven health-management platforms, but it remains financially and operationally fragile. The auditor transition is procedural, not a business advance. CBIZ was dismissed and Withum was engaged for the fiscal year ending December 31, 2026; the filing reports no accounting disagreements or reportable events tied to the change. 〔0〕 The negative signal is that the underlying reporting problems remain open. The company says its prior audit still carried substantial doubt about its ability to continue as a going concern, while weaknesses involving segregation of duties, review controls, valuation expertise, and U.S. GAAP accounting had not been remediated as of June 30, 2026. 〔1〕 The new auditor may improve oversight, but this filing does not show remediation or improved liquidity. That makes the change more consequential than a routine firm rotation: it puts the company’s financial-reporting infrastructure back in focus without changing the underlying operating story. Bottom line: This is an auditor handoff, not a strategic milestone. The filing modestly worsens the story because unresolved controls and the going-concern warning remain active issues, while offering no evidence they are fixed.
2026 annual audit and updated control assessment
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!